Background: Helicobacter pylori infection is one of the main risk factors for non-cardia gastric cancer.
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Introduction
In spite of a marked decreasing trend in its incidence and mortality in the last decades, gastric cancer continues to be the third leading cause of cancer death in the world. Almost one million of new gastric cancer cases were estimated to occur in 2012, accounting for 7% of all incident cases of cancer worldwide, and 723,073 deaths were reported in the same year (9% of the total cancer deaths). Mortality rates are especially high in certain areas such as Eastern Asia, Central and Eastern
Europe and South America [1, 2] . In 2012, the estimated number of new gastric cancer cases in Spain was 7,810, and the number of registered deaths was 5,675; the corresponding age-standardized incidence and mortality rates (European Standard Population) were 16.4 per 100,000 population in men and 7.5 in women [3] , and 11.3 per 100,000 population in men and 5.2 in women, respectively [4] .
Geographic variations have also been observed within countries [5] [6] [7] . In Spain, gastric cancer mortality displays a singular geographical pattern, with higher mortality rates in Central and
Northern regions [8, 9] . This pattern, characterized by its persistence in time and its similarity in both sexes, has not changed substantially over the last decades [10, 11] . Although differences in mortality among regions can be partially associated with different dietary habits or with territorially-related environmental exposures, the implication of Helicobacter Pylori (H. pylori) infection in the observed pattern is uncertain.
Chronic infection with H. pylori is the strongest established causal factor for the development of gastric cancer [12] . This association has been reported to be higher, and even limited to, cancer localized distal to the esophagogastric junction, the so called non-cardia gastric cancer, with risk estimates around 2.8 for non-cardia gastric cancer and 1.1 for cardia gastric cancer [13] . The prevalence of H. pylori infection is over 50% worldwide, with marked geographical variations [14] .
Though higher prevalence is usually reported for developing countries [15] [16] [17] , prevalences over 70% have been reported in specific Western populations, including some Portuguese and Spanish regions [18] [19] [20] . Fortunately, only about 1% of the infected people develop a gastric cancer. Specific microbial strains and phenotypes have been linked to a higher risk of gastric cancer, and are now recognized virulence factors [21, 22] . Also, different host and environmental factors have been shown to interact and modulate individual risk [23, 24] . However, important issues such as how to identify infected people at higher risk of developing gastric cancer remain poorly understood.
Multiplex serology is a recently developed technique that allows the simultaneous and quantitative detection of antibodies directed against different antigens in a high throughput assay, which makes this technique appropriate for large epidemiological studies [25] . By means of multiplex serology we quantified antibody reactivities against a wide range of H. pylori proteins in a well characterized group of gastric cancer cases and healthy controls.
The aim of this study is to assess the relationship between serological reactivity to 16 H. pylori proteins and the development of gastric cancer, differentiating non-cardia and cardia gastric cancer, in order to identify serological markers of gastric cancer risk.
Methods
Study population
MCC-Spain study (www.mccspain.org) is a multicase-control study with population controls that was carried out in 12 Spanish provinces to study environmental and genetic risk factors for five types of tumours: colorectal, breast, oesophagogastric, prostate and chronic lymphocytic leukaemia [26] .
Cases were recruited between 2008 and 2013 in 23 hospitals and controls were frequency-matched to cases by age, sex and region (province). In each province at least two types of cancer cases were recruited, and a common set of controls was selected for all their cases. To obtain an age and sex frequency-matched sample, an initial estimation of the expected distribution of this variables among cases recruited in each province was made, taking into account data from the Spanish cancer registries. When the recruitment of cases finished, homogeneity in the age-sex distribution between cases and controls was checked, and additional controls were recruited when needed, to assure the availability, in each province, of at least one control of the same sex and age (+/-5 years) for each case. Selection of controls was done through a random procedure from the General Practitioner's lists at primary healthcare centers of the hospitals' catchment areas. Potential controls were contacted by phone and, if they agree to participate, they were scheduled for a face-to-face interview. Cases and controls had to fulfill the following selection criteria: to have lived for at least 6 months in the study areas, to be 20-85 years old and to able to answer the epidemiological questionnaire. Gastric cancer cases were recruited in 15 hospitals from 9 Spanish provinces (Asturias, Barcelona, Cantabria, Granada, Huelva, León, Madrid, Navarra and Valencia). Eligible cases included histologically confirmed incident gastroesophageal cancer cases (International Classification of Diseases 10th Revision (ICD-10) codes C16, D00.2 or C15.5) diagnosed during the recruitment period and with no personal history of gastroesophageal cancer. We also recruited cases with tumour in the lower third of the oesophagus to be able to include all adenocarcinomas of the oesophagogastric junction. Cases were classified as cardia, non-cardia and others (tumors overlapping cardia and noncardia or with non-specified gastric location). We identified 923 gastric cancer cases and 7734 controls potentially eligible. Response rates varied by centre and on average were 54.6% in cases and 53.0% in controls. Among the common set of controls, for this analysis we excluded those with personal history of gastroesophagic cancer, those from provinces that did not recruit gastric cancer cases and those younger than the youngest gastric cancer case in each province. Finally, 459 cases and 3 440 matched controls fulfilled selection criteria. All the participants answered an epidemiological questionnaire administered through personal interviews by trained personnel and were asked for donation of biological samples (blood, urine, hair and nails). The study protocol was approved by the Review Board of the participating institutions and all the included subjects gave written informed consent to participate.
Serological characterization
Blood samples were refrigerated locally until being processed and aliquoted in the first 48 hours.
Then, they were stored at -80°C. Seroreactivities against 16 H. pylori proteins were determined using H. pylori multiplex serology (Online Resource 1). Multiplex serology is a glutathione S-transferase capture immunosorbent assay combined with fluorescent-bead technology, as described elsewhere [27] . This technique simultaneously quantifies antibodies directed against arrays of protein antigens.
In brief, bacterially expressed recombinant glutathione S-transferase-H. pylori fusion proteins were Following previously published criteria, H. pylori seropositivity was defined as positivity for at least 4 of the 15 H. pylori proteins (excluding HomB, a protein recently added to H. pylori multiplex serology), and subjects fulfilling this criteria were considered infected [25] .
Statistical analyses
Association of proposed gastric cancer risk factors with both, case-control status and H. pylori serostatus in controls, was analysed by means of Chi-squared test.
To study the association between serological results and gastric cancer, odds ratios (OR) and 95%
confidence intervals (95% CI) were estimated using multilevel logistic regression mixed models, with province as a random effect term and the following variables as fixed effects terms: age, sex, education, smoking status and gastric cancer family history. This analysis was performed in the overall sample to assess the effect of H. pylori seropositivity.
Then, to identify infected people at higher risk of developing gastric cancer, analyses assessing serostatus of individual proteins were performed in the infected subsample. Dose-response relationship was additionally explored using restricted cubic spline functions to assess potential departures from linearity. For this purpose seroreactivity values were log-transformed and subjects with values under percentile 1 or over percentile 99 were excluded. Subsequently, to study the independent effect of seropositiviy against proteins found to be associated with non-cardia cancer risk at a p-value<0.10, a multivariable logistic regression model was fitted simultaneously including serostatus of all of them in addition to potential confounding factors.
Finally, to account for a possibly high collinearity among antibody reactivities against analysed proteins, and in order to identify antibody response patterns, a principal components analysis was carried out. The principal components analysis was performed using the control population, and reactivity values of each tested antibody were standardized to a mean of 0 and a standard deviation of 1. Selection of relevant components was done taking into account obtained eigenvalues and clinical interpretability of the components arising from the analysis. To assess the relationship of the selected components with non-cardia gastric cancer risk, the score for each component was calculated for each case and control. Then scores were categorized, according to quartiles of their distribution among controls, and included in a multivariable logistic regression mixed model, to estimate the association between gastric cancer risk and the obtained components. These models were adjusted by the same covariates as the models described above (with province as a random effect term and age, sex, education, smoking status and gastric cancer family history as fixed effects terms).
Results
Among participants fulfilling selection criteria, H. pylori serostatus could be determined in 281 cases (202 non-cardia gastric cancer, 62 cardia gastric cancer, 9 located in the esophageal lower third and 8
with overlapping or not classifiable tumor location) and 2 071 matched controls, and were therefore included in the present analyses. The other participants had no multiplex serology results (no consent for blood sample collection or sample not processed) or their serological results were considered as non-valid (glutathione S-transferase>300 median reporter fluorescence intensity) (two cases). (Table 2 ).
In controls, seropositivity to individual H. pylori proteins ranged from 31% (Cad) to 83% (GroEL) Among infected subjects, seropositivity to eight of the analysed H. pylori proteins showed a statistically significant or almost significant association with non-cardia gastric cancer ( Figure 1 ): six were associated with a lower risk (UreA, HP231, NapA, Cagδ, Catalase and HcpC) and two (CagA and VacA) with a higher risk. With respect to cardia gastric cancer, HP305 and Cagδ appeared associated with a lower risk (in the limit of the statistical significance). Dose-response association with noncardia cancer for these nine proteins can be visualized in Figure 2 , again including only participants classified as H. pylori seropositive. A decreasing OR from the seropositivity cut-off value upward was estimated for UreA, NapA, Cagδ, Catalase and HcpC, while the opposite effect was estimated for
CagA and, to a lesser extent, for VacA. For HP305 and HP231, higher risks were estimated for median reporter fluorescence intensity levels under the cut-off. For UreA, NapA, HP305, CagA, HcpC and GroEL (the latter not included in Figure 2 ) relationship with non-cardia cancer departed from linearity (p<0.05).
Results were qualitatively similar between men and women, and between those under and over 65 years old. No differences in the direction of the effects were present and, where differences in the magnitude of the ORs were observed, confidence intervals overlapped (data not shown).
When mutually adjusting by serostatus against those proteins associated at a p-value<0. Table 3 shows the associations of each component with non-cardia gastric cancer risk among H. pylori infected subjets. High scores in the first component were associated with a 60% lower risk of non-cardia gastric cancer (fourth vs. first quartile). On the other hand, high scores in the second component were associated with a threefold increased risk.
Discussion
The high prevalence of H. pylori infection and the relatively low incidence of non-cardia gastric cancer even among those infected, render the identification of markers of increased or decreased cancer risk a crucial issue to decide how to manage the infection, both at individual and at population level. In this study we have identified two patterns of antibody reactivity against 16 H.
pylori proteins related to different risk of non-cardia gastric cancer: a pattern characterized by the concomitant presence of high antibody reactivities against a range of different proteins, which was associated with a lower risk, and another one characterized by high antibody reactivities against the main recognized H. pylori virulence factors, CagA and VacA, which was associated with a higher risk.
Interestingly, in our control population these two patterns show some parallelism with the type of H.
pylori strain causing the infection [28] . Those infected by a type I H. pylori strain (defined by a seroreactivity against CagA higher than 9000 median reporter fluorescence intensity, following published criteria for multiplex serology [25] ) presented lower scores in the first component and higher scores in the second one than those infected by a type II strain (data not shown). Therefore, the first pattern could represent an H. pylori type II infection ("non-virulent pattern") and the second one a type I infection ("virulent pattern").
The analyses of serostatus of proteins individually, showed that, after adjusting by main gastric cancer risk factors, infected people seropositive to CagA or VacA had and increased risk of non-cardia gastric cancer compared to those infected but seronegative to these proteins. On the other hand, infected people seropositive to Cagδ, UreA, HP231 or NapA had a lower risk. When including in the same model serostatus against these proteins, only CagA and Cagδ remained associated with noncardia gastric cancer in a statistically significant manner. The dose-response analysis showed a statistically significant trend with intensity of antibody reactivity for both of them, giving some support for a real association. CagA is a well-recognized H. pylori virulence factor that has been related to atrophic gastritis and non-cardia gastric cancer. On the other hand, the exact function of Cagδ is still not well understood [29] . This protein is a component of the T4SS (type 4 secretion system) of H. pylori. The major role of this T4SS is thought to be the translocation of the CagA effector protein into the host cell, but CagA-independent pathogenicity pathways, such as the induction of IL-8 production from the host, have also been suggested [30] . There is not consistency among the results from different studies in the possible role of serostatus to Cagδ as a marker of lower non-cardia gastric cancer risk. Therefore, this finding should be taken cautiously until more evidence becomes available [31] [32] [33] [34] [35] .
Recent studies using H. pylori multiplex serology have also found statistically significant inverse relationships between seropositivity against some H. pylori proteins, such as CagM [35] , GroEL and NapA [33] , and gastric cancer risk, but others have not [31, 32, 34] . In a case-control study carried out in Sweden [32] , a non-statistically significant lower risk of non-cardia gastric cancer was associated with seropositivity to the same four proteins identified in our study ( Some methodological differences among studies could help to explain the differences with our findings. First, statistical analyses performed to identify serological virulence markers in our study have been restricted to subjects classified as infected (positive to 4 or more H. pylori proteins), in contrast to other studies, where the overall sample (infected and non-infected) was considered.
However, we repeated our analyses in the overall sample, and not noteworthy differences appeared between the two approaches (data not shown). Second, differences in patient selection criteria, such as the exclusion of patients with atrophic gastritis [31] , may lead to increased risk estimations. Third, the prevalence of H. pylori infection and of seropositivity to each protein differ among studies. High prevalences of exposure among controls, like in our sample, tend to reduce the magnitude of ORs in case-control studies [36, 37] . Nevertheless, real differences among countries in the predominant bacterial strains and in host genetics and environmental factors cannot be ruled out as an explanation for different results among studies. This would be in accordance with the importance generally attributed to geographical variations in the epidemiology of both, H. pylori infection and gastric cancer [38] [39] [40] .
Limitations of our study include the case-control design, which limits the possibility to demonstrate a cause to effect direction of the associations. Therefore, a possible impact on our results of changes in H. pylori serostatus secondary to the disease or its treatment cannot be completely ruled out. To explore the possibility of reverse causation in our data, we performed stratified analyses by cancer stage and by treatment status at the moment of blood sample collection. No remarkable differences appeared in the estimated ORs between tumoral stage subgroups. Meanwhile, we observed some indications of a higher OR for the association between H. pylori infection and non-cardia gastric cancer risk among those not having received cancer therapy, compared to those that had received some treatment (data not shown).
With regard to the criteria used to define infection (seropositivity for ≥4 proteins by multiplex serology), it should be noted that it has not been validated in our sample. However, this definition has been contrasted with standard ELISA and Western blot assays in other populations, showing acceptable validity [25] . Another limitation is the lack of information about the presence of atrophic gastritis, a factor that can exert a confounding effect on the association between serological status and non-cardia gastric cancer risk [31] [32] [33] [41] [42] [43] . Nonetheless, the high sensitivity of the multiplex serology could minimize the impact that factors related to the persistence of the serological response, such as those mentioned, may have on the assessment of associations between infection diagnosed by serological techniques, and disease. Lastly, both the relatively low sample size and the mild-moderate correlation among antibody reactivities against different proteins, reduce statistical power, especially to perform subgroup analyses.
In spite of these limitations, our study included an acceptable number of incident gastric cancer patients including cardia as well as non-cardia gastric cancer, and a broad sample of population controls, and was conducted following a meticulous methodology which allowed gathering precise information for the most important recognized risk factors for this disease. Besides, estimating risks for the infected subjects instead of the whole sample, represents a novel approach that enriches previous knowledge, once the carcinogenic role of H. pylori in non-cardia gastric cancer has been generally accepted. This approach, applied to an H. pylori infection defined as seropositivity to four or more bacterial proteins, also contributes to reduce the possible classification error derived from eventual false positive results in serostatus against a single protein. In addition, our results complement data derived from other regions, which is an important issue for a disease characterized by high geographical variations. In this respect, due to geographical and historical characteristics, the Spanish population has coexisted with a diversity of populations from other origins, which may have influenced its genetic background, and its response to H. pylori colonization. The high prevalence of infection identified in this study does not have a reflection in the gastric cancer incidence or mortality rates in Spain, which are similar to or lower than the European average [2] . This could suggest that there are differences with respect to other populations either in the characteristics of the circulating H. pylori strains, in the host response to the infection or in environmental factors.
Investigating whether the antibody reactivity patterns identified in this study are also present in other populations, and whether they are also associated with the risk of non-cardia gastric cancer would be of value to contribute to the understanding of geographical differences.
In summary, according to our results people with H. pylori infection that have high reactivities against CagA and VacA would have an increased risk of non-cardia gastric cancer. Additionally, we have identified a group that, in spite of have being infected by the bacteria, would experience a low risk of non-cardia gastric cancer. This group would be characterized by high concomitant seroreactivities against many H. pylori proteins, particularly against UreA, HP231, NapA, HyuA and Catalase.
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Title: Correlation of seroreactivity to the 16 studied H. pylori proteins in infected participants Caption: Numbers represent Spearman rho coefficient.
